Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of ARS Pharmaceuticals in a research report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback